Drug Profile
Research programme: monoclonal antibody therapeutics - A-CUBE/Chugai Pharmaceutical
Latest Information Update: 20 Dec 2010
Price :
$50
*
At a glance
- Originator A-CUBE
- Developer A-CUBE; Chugai Biopharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 15 Dec 2010 Investigation in Undefined indication in USA (unspecified route)